# CODEXIS, INC. (CDXS)

Informational only - not investment advice.

CIK: 0001200375
SIC: 2860 Industrial Organic Chemicals
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2860 Industrial Organic Chemicals](/industry/2860/)
Latest 10-K filed: 2026-03-11
SEC page: https://www.sec.gov/edgar/browse/?CIK=1200375
Filing source: https://www.sec.gov/Archives/edgar/data/1200375/000120037526000006/cdxs-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-11 · accession 0001200375-26-000006 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001200375.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 70,387,000 USD | 2025 | verified |
| Net income | -43,974,000 USD | 2025 | verified |
| Assets | 147,797,000 USD | 2025 | verified |
| Free cash flow | -23,847,000 USD | 2025 | computed |
| Net margin | -62.47% | 2025 | computed |
| Operating margin | -59.30% | 2025 | computed |
| Revenue YoY | +18.61% | 2025 | computed |
| ROE | -87.03% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | CDXS | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -62.5% | -4.5% | 0 | 10 |
| Operating margin | -59.3% | -3.5% | 0 | 9 |
| Revenue growth | 18.6% | -3.7% | 89 | 10 |
| FCF margin | -33.9% | 1.8% | 11 | 10 |
| ROE | -87.0% | -7.3% | 0 | 12 |
| ROA | -29.8% | -3.4% | 0 | 12 |
| Liabilities / equity | 1.92 | 0.92 | 82 | 12 |
| Current ratio | 3.82 | 2.39 | 64 | 12 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2860 Industrial Organic Chemicals, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 70387000 | USD | 2025 | 2026-03-11 |
| Net income | -43974000 | USD | 2025 | 2026-03-11 |
| Assets | 147797000 | USD | 2025 | 2026-03-11 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-11. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001200375.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 48,837,000 | 50,024,000 | 60,594,000 | 68,458,000 | 69,056,000 | 104,754,000 | 138,590,000 | 70,143,000 | 59,345,000 | 70,387,000 |
| Net income | -8,558,000 | -22,996,000 | -10,878,000 | -11,935,000 | -24,010,000 | -21,279,000 | -33,592,000 | -76,240,000 | -65,276,000 | -43,974,000 |
| Operating income | -8,564,000 | -22,970,000 | -11,295,000 | -12,549,000 | -23,920,000 | -22,697,000 | -34,881,000 | -68,069,000 | -58,519,000 | -41,739,000 |
| Diluted EPS |  |  |  | -0.21 | -0.40 | -0.33 | -0.51 | -1.12 | -0.89 | -0.50 |
| Operating cash flow | -1,860,000 | -8,755,000 | -14,094,000 | -12,560,000 | -16,464,000 | -14,267,000 | 11,284,000 | -52,638,000 | -49,410,000 | -19,376,000 |
| Capital expenditures | 888,000 | 985,000 | 2,768,000 | 3,730,000 | 3,748,000 | 13,828,000 | 8,307,000 | 4,418,000 | 4,305,000 | 4,471,000 |
| Assets | 35,648,000 | 53,625,000 | 79,283,000 | 149,073,000 | 221,646,000 | 246,383,000 | 250,393,000 | 136,561,000 | 149,011,000 | 147,797,000 |
| Liabilities | 16,549,000 | 29,078,000 | 22,977,000 | 43,556,000 | 51,543,000 | 81,992,000 | 105,596,000 | 49,946,000 | 82,084,000 | 97,268,000 |
| Stockholders' equity | 19,099,000 | 24,547,000 | 56,306,000 | 105,517,000 | 170,103,000 | 164,391,000 | 144,797,000 | 86,615,000 | 66,927,000 | 50,529,000 |
| Cash and cash equivalents | 19,240,000 | 31,219,000 | 53,039,000 | 90,498,000 | 149,117,000 | 116,797,000 | 113,984,000 | 65,116,000 | 19,264,000 | 50,793,000 |
| Free cash flow | -2,748,000 | -9,740,000 | -16,862,000 | -16,290,000 | -20,212,000 | -28,095,000 | 2,977,000 | -57,056,000 | -53,715,000 | -23,847,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | -17.52% | -45.97% | -17.95% | -17.43% | -34.77% | -20.31% | -24.24% | -108.69% | -109.99% | -62.47% |
| Operating margin | -17.54% | -45.92% | -18.64% | -18.33% | -34.64% | -21.67% | -25.17% | -97.04% | -98.61% | -59.30% |
| Return on equity | -44.81% | -93.68% | -19.32% | -11.31% | -14.11% | -12.94% | -23.20% | -88.02% | -97.53% | -87.03% |
| Return on assets | -24.01% | -42.88% | -13.72% | -8.01% | -10.83% | -8.64% | -13.42% | -55.83% | -43.81% | -29.75% |
| Liabilities / equity | 0.87 | 1.18 | 0.41 | 0.41 | 0.30 | 0.50 | 0.73 | 0.58 | 1.23 | 1.92 |
| Current ratio | 2.20 | 1.81 | 3.77 | 7.42 | 7.38 | 4.85 | 3.32 | 2.61 | 4.18 | 3.82 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-11. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001200375.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.15 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.34 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.17 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 9,277,000 | -34,908,000 | -0.50 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 26,561,000 | -7,192,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 17,073,000 | -11,505,000 | -0.16 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 7,979,000 | -22,755,000 | -0.32 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 12,833,000 | -20,640,000 | -0.29 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 21,460,000 | -10,376,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 7,543,000 | -20,688,000 | -0.25 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 15,328,000 | -13,272,000 | -0.16 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 8,601,000 | -19,615,000 | -0.22 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 38,915,000 | 9,601,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 15,248,000 | -8,704,000 | -0.10 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 14,915,000 | -12,005,000 | -0.13 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from CDXS's latest 10-K: [/company/CDXS/business/](/company/CDXS/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from CDXS's latest 10-K: [/company/CDXS/risk-factors/](/company/CDXS/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1200375/000120037526000019/cdxs-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-11
Report date: 2026-06-30

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management's discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management's discussion and analysis of financial condition and results of operations for the year ended December 31, 2025 included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 11, 2026 (the “Annual Report”). This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, but are not limited to, expectations regarding our strategy, business plans, financial performance and developments relating to our industry. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part II, Item 1A: “Risk Factors” of this Quarterly Report on Form 10-Q and Part I, Item 1A: “Risk Factors” of our Annual Report, and elsewhere in this report. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

Business Overview

We are a leading provider of technology solutions to improve therapeutics manufacturing. We focus on impacting the manufacturing process by using our proprietary CodeEvolver directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. Enzymes are naturally occurring biological molecules critical to almost all biochemical reactions. They can be precisely engineered and optimized for specific functions, and to have particular characteristics, such as an ability to survive environments in which natural enzymes cannot, or to perform (bio)chemical transformations that are different than those for which they naturally evolved. We employ our technology and expertise to enhance the properties and performance of enzymes to drive pivotal improvements in manufacturing of complex therapeutics across two key areas:

ECO Synthesis manufacturing platform

Our ECO Synthesis® manufacturing platform is comprised of enzymatic tools and processes that are designed to enable large-scale manufacture of RNA interference (“RNAi”) therapeutics. We use the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics in production processes that deliver improvements, including purity, yield, and manufacturing efficiency. In November 2024, we presented data at the TIDES Europe conference demonstrating the successful end-to-end enzymatic synthesis of an entire commercially approved small interfering ribonucleic acid (“siRNA”) therapeutic asset with the ECO Synthesis manufacturing platform. In addition to using full enzymatic sequential synthesis, adding one nucleotide at a time to synthesize the two strands from beginning to end, we demonstrated synthesis of the same siRNA asset using three other routes utilizing enzymatic ligation with our double-stranded RNA (“dsRNA”) ligase, which can stitch together fragments of chemically and/or enzymatically synthesized RNA to form the full siRNA drug structure. For the three other routes, our data highlighted that full-length oligonucleotides of equal quality and yields were obtained whether the fragments were made with enzymes or by traditional solid phase oligonucleotide synthesis (“SPOS”) (current standard production route for oligonucleotide manufacturing).

21

At the end of 2024, we completed the build out of our ECO Synthesis Innovation Lab, a facility where our ECO Synthesis manufacturing platform is deployed to synthesize gram-scale quantities of a customer’s desired siRNA construct suitable for pre-clinical testing. In addition, the infrastructure allows us to provide process development, analytical method development and other manufacturing process optimization which is required to enable the siRNA to proceed to clinical-stage manufacturing and testing. In 2025, we successfully manufactured non-good manufacturing practice (“GMP”)-grade siRNA drug substance for customers in our Innovation Lab under development services contracts. We also entered into partnerships with three large-scale contract development and manufacturing organizations (“CDMOs”) to evaluate our ECO platform of enzymatic tools and processes to ultimately synthesize GMP-grade siRNA drug substance for our customers. Under each of these agreements, we have conducted technology transfer to several partners in 2026 for further evaluation of the technology. We believe these relationships to be a vital extension of our strategy to be a technology solutions provider for our customers. Through these arrangements, our customers will have access to proven, large-scale commercial manufacturers who are familiar with our process, who can then offer a seamless manufacturing scale-up of our customers’products. We expect to expand our enzymatic tools and process offerings as we further enhance the ECO Synthesis platform to address the overall market needs for scalable and sustainable RNAi manufacturing.

In November 2025, we signed a lease for a 34,000-square-foot GMP manufacturing facility in Hayward, California, which we refer to as our ECO GMP Manufacturing Center. The multi-purpose facility is designed to expand our internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using our ECO Synthesis manufacturing platform, and its flexible design is also intended to support production of purified enzymes used in the ECO Synthesis process. We applied for a building permit during the second quarter of 2026 and expect to commence retrofit construction during the second half of 2026. We expect the facility to support customers’ early clinical trial supply requirements. Our CDMO partnerships and the ECO GMP Manufacturing Center are complementary elements of our strategy: the ECO GMP Manufacturing Center is intended to serve early clinical-stage supply, while our CDMO partners are intended to provide large-scale commercial manufacturing capacity.

Small molecule pharma biocatalysis

In our small molecule pharma biocatalysis business, we utilize our CodeEvolver technology platform to develop optimized enzymes that are used by some of the world’s largest pharmaceutical companies to improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. Our unique enzymes drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, all of which lead to improved efficiency and reduced costs in small-molecule manufacturing.

22

Results of Operations

The following table shows the amounts from our unaudited condensed consolidated statements of operations for the periods presented (in thousands, except percentages):

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Change","","Six Months Ended June 30,","","Change"],["","2026","","2025","","$","","%","","2026","","2025","","$","","%"],["Revenues:"],["Product revenue","$","13,218","","","$","7,380","","","$","5,838","","","79","%","","$","20,409","","","$","13,439","","","$","6,970","","","52","%"],["Research and development revenue","1,697","","","7,948","","","(6,251)","","","(79)","%","","9,754","","","9,432","","","322","","","3","%"],["Total revenues","14,915","","","15,328","","","(413)","","","(3)","%","","30,163","","","22,871","","","7,292","","","32","%"],["Costs and operating expenses:"],["Cost of product revenue","3,512","","","2,098","","","1,414","","","67","%","","5,576","","","4,830","","","746","","","15","%"],["Research and development","11,705","","","13,775","","","(2,070)","","","(15)","%","","23,153","","","26,717","","","(3,564)","","","(13)","%"],["Selling, general and administrative","10,927","","","12,317","","","(1,390)","","","(11)","%","","20,706","","","24,672","","","(3,966)","","","(16)","%"],["Total costs and operating expenses","26,144","","","28,190","","","(2,046)","","","(7)","%","","49,435","","","56,219","","","(6,784)","","","(12)","%"],["Loss from operations","(11,229)","","","(12,862)","","","1,633","","","(13)","%","","(19,272)","","","(33,348)","","","14,076","","","(42)","%"],["Interest income","535","","","584","","","(49)","","","(8)","%","","1,200","","","1,335","","","(135)","","","(10)","%"],["Interest and other expense, net","(1,301)","","","(984)","","","(317)","","","32","%","","(2,591)","","","(1,926)","","","(665)","","","35","%"],["Loss before income taxes","(11,995)","","","(13,262)","","","1,267","","","(10)","%","","(20,663)","","","(33,939)","","","13,276","","","(39)","%"],["Provision for income taxes","10","","","10","","","\u2014","","","\u2014","%","","46","","","21","","","25","","","119","%"],["Net loss","$","(12,005)","","","$","(13,272)","","","$","1,267","","","(10)","%","","$","(20,709)","","","$","(33,960)","","","$","13,251","","","(39)","%"]]
[[/GREPCENT_TABLE]]

Revenues

Our revenues consisted of product revenue and research and development revenue as follows:

•Product revenue consists of sales of biocatalysts used in the manufacture of small molecule active pharmaceutical intermediates, enzymes such as dsRNA ligase used in the manufacture of siRNA molecules, enzymes for the molecular biology and diagnostic markets, and Codex™ biocatalyst panels and kits.

•Research and development revenue includes license, technology access and exclusivity fees, research services fees, milestone payments, royalties, optimization and screening fees.

Revenues are as follows (in thousands, except percentages):

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Change","","Six Months Ended June 30,","","Change"],["","2026","","2025","","$","","%","","2026","","2025","","$","","%"],["Product revenue","$","13,218","","","$","7,380","","","$","5,838","","","79","%","","$","20,409","","","$","13,439","","","$","6,970","","","52","%"],["Research and development revenue","1,697","","","7,948","","","(6,251)","","","(79)","%","","9,754","","","9,432","","","322","","","3","%"],["Total revenues","$","14,915","","","$","15,328","","","$","(413)","","","(3)","%","","$","30,163","","","$","22,871","","","$","7,292","","","32","%"]]
[[/GREPCENT_TABLE]]

Revenues typically fluctuate on a quarterly basis due to the variability in our customers' manufacturing schedules and the timing of our customers’ clinical trials. In addition, we have limited internal capacity to manufacture enzymes. As a result, we are dependent upon the performance and capacity of third-party manufacturers for the commercial scale manufacturing of the enzymes used in our pharma

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1200375/000120037526000006/cdxs-20251231.htm
Complete FY 2025 MD&A: /company/CDXS/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-11
Report date: 2025-12-31

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management's discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited consolidated financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, but are not limited to, expectations regarding our strategy, business plans, financial performance and developments relating to our industry. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A: "Risk Factors," of this Annual Report on Form 10-K and elsewhere in this report. The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.

Business Overview

We are a leading provider of technology solutions to improve therapeutics manufacturing. We focus on impacting the manufacturing process by using our proprietary CodeEvolver directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. Enzymes are naturally occurring biological molecules critical to almost all biochemical reactions. They can be precisely engineered and optimized for specific functions, and to have particular characteristics, such as an ability to survive environments in which natural enzymes cannot, or to perform (bio)chemical transformations that are different than those for which they naturally evolved. We employ our technology and expertise to enhance the properties and performance of enzymes to drive pivotal improvements in manufacturing of complex therapeutics across two key areas:

ECO Synthesis manufacturing platform

Our ECO Synthesis® manufacturing platform is comprised of enzymatic tools and processes that are designed to enable large-scale manufacture of RNA interference (“RNAi”) therapeutics. We use the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics in production processes that deliver improvements, including purity, yield, and manufacturing efficiency. In November 2024, we presented data at the TIDES Europe conference demonstrating the successful end-to-end enzymatic synthesis of an entire commercially approved small interfering ribonucleic acid (“siRNA”) therapeutic asset with the ECO Synthesis manufacturing platform. In addition to using full enzymatic sequential synthesis, adding one nucleotide at a time to synthesize the two strands from beginning to end, we demonstrated synthesis of the same siRNA asset using three other routes utilizing enzymatic ligation with our double-stranded RNA (“dsRNA”) ligase, which can stitch together fragments of chemically and/or enzymatically synthesized RNA to form the full siRNA drug structure. For the three other routes, our data highlighted that full-length oligonucleotides of equal quality and yields were obtained whether the fragments were made with enzymes or by traditional solid phase oligonucleotide synthesis (“SPOS”) (current standard production route for oligonucleotide manufacturing). At the end of 2024, we completed the build out of our ECO Synthesis Innovation Lab, a facility where our ECO Synthesis manufacturing platform is deployed to synthesize gram-scale quantities of a customer’s desired siRNA construct suitable for pre-clinical testing. In addition, the infrastructure allows us to provide process development, analytical method development and other manufacturing process optimization which is required to enable the siRNA to proceed to clinical-stage manufacturing and testing. In 2025, we successfully manufactured non-good manufacturing practice (“GMP”)-grade siRNA drug substance for customers in our Innovation Lab under development services contracts. We also entered into partnerships with three large-scale contract development and manufacturing organizations (“CDMOs”) to evaluate our ECO platform of enzymatic tools and processes to ultimately synthesize GMP-grade siRNA drug substance for our customers. In each of these agreements, we are currently in the feasibility testing stage and expect to advance at least one of these partnerships, including initiating a technology transfer to that organization, in 2026. We believe these relationships to be a vital extension of our strategy to be a technology solutions provider for our customers. Through these arrangements, our customers will have access to proven, large-scale commercial manufacturers who are familiar with our process, who can then offer a seamless manufacturing scale-up of our customers’ products. We expect to expand our enzymatic tools and process offerings as we further enhance the ECO Synthesis platform to address the overall market needs for scalable and sustainable RNAi manufacturing.

48

Small molecule pharma biocatalysis

In our small molecule pharma biocatalysis business, we utilize our CodeEvolver technology platform to develop optimized enzymes that are used by some of the world’s largest pharmaceutical companies to improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. Our unique enzymes drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, all of which lead to improved efficiency and reduced costs in small-molecule manufacturing.

Financing Activities

In May 2021, we filed a Registration Statement on Form S-3 with the SEC, that automatically became effective upon its filing, under which we may sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings. On February 27, 2023, we filed a post-effective amendment to that Registration Statement on Form S-3. Pursuant to that post-effective amendment, we registered an aggregate $200.0 million of securities. In May 2021, we entered into an Equity Distribution Agreement (“EDA”) with Piper Sandler & Co. (“PSC”), under which PSC, as our exclusive agent, at our discretion and at such times that we determined from time to time, may have sold over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. Under the terms of the EDA, PSC was permitted to sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”). We were not required to sell any shares at any time during the term of the EDA. On April 24, 2024, we terminated the EDA. No shares of our common stock were issued and sold pursuant to the EDA during the year ended December 31, 2024. During the year ended December 31, 2023, 3,079,421 shares of our common stock were issued and sold pursuant to the EDA for gross proceeds of $8.7 million, or $7.9 million in net proceeds after PSC's commissions and direct offering expenses of $0.7 million.

On May 2, 2024, we entered into a Controlled Equity Offering Sales℠ Agreement (the “Cantor Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), under which Cantor, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $75.0 million of shares of our common stock. Under the terms of the Cantor Sales Agreement, Cantor may sell the shares at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act. On May 2, 2024, we filed a registration statement on Form S-3 registering the offer and sale of these shares under the Securities Act which became effective on May 14, 2024. We will pay a commission of up to 3.0% of gross sales proceeds of any common stock sold under the Cantor Sales Agreement. In 2024, 10,440,000 shares of our common stock were issued and sold pursuant to the Cantor Sales Agreement and we received net proceeds of $29.7 million after Cantor’s commissions and direct offering expenses. During the year ended December 31, 2025, 7,244,966 shares of our common stock were issued and sold pursuant to the Cantor Sales Agreement, all during the second quarter of 2025, and we received net proceeds of $16.4 million after Cantor’s commissions and direct offering expenses. As of December 31, 2025, $26.4 million remained available for sale under the Cantor Sales Agreement.

On February 13, 2024, we entered into a five-year term loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”), an affiliate of Innovatus Capital Partners, LLC, as Lender, consisting of up to two tranches, of which the first tranche of $30.0 million was disbursed upon execution of the Loan Agreement and the second tranche of $10.0 million was funded on June 27, 2025 upon achievement of certain financial milestones. The Term Loan carries an interest-only period of 36 months (with the possibility to extend up to 48 months upon achievement of certain pre-specified financial milestones) and will bear interest at a floating rate of the sum of (a) the greater of (i) prime rate and (ii) 7.50%, plus (b) 3.25%.

49

RESULTS OF OPERATIONS

The following table shows the amounts from our consolidated statements of operations for the periods presented (in thousands, except percentages):

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/CDXS/mda/fy2025/
All MD&A years: /company/CDXS/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/CDXS/mda/fy2024/): filed 2025-02-27; accession 0001200375-25-000003 (https://www.sec.gov/Archives/edgar/data/1200375/000120037525000003/cdxs-20241231.htm)
- [FY 2023 MD&A](/company/CDXS/mda/fy2023/): filed 2024-02-28; accession 0001200375-24-000009 (https://www.sec.gov/Archives/edgar/data/1200375/000120037524000009/cdxs-20231231.htm)
- [FY 2022 MD&A](/company/CDXS/mda/fy2022/): filed 2023-02-27; accession 0001200375-23-000012 (https://www.sec.gov/Archives/edgar/data/1200375/000120037523000012/cdxs-20221231.htm)
- [FY 2021 MD&A](/company/CDXS/mda/fy2021/): filed 2022-02-28; accession 0001200375-22-000010 (https://www.sec.gov/Archives/edgar/data/1200375/000120037522000010/cdxs-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2860 Industrial Organic Chemicals) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/CDXS.md · JSON record: /company/CDXS.json · verified financials: /company/CDXS/financials.json / /company/CDXS/financials.csv · machine TOC for the whole site: /llms.txt